BrainsWay Ltd. (BWAY) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
44.16
↑+59% vs avg
5yr avg: 27.77
30Y Low23.8·High31.7
P/FCF
↓
19.63
+5% vs avg
5yr avg: 18.76
30Y Low12.3·High25.2
P/B Ratio
↑
4.76
↑+117% vs avg
5yr avg: 2.19
30Y Low0.9·High4.3
ROE
↑
11.4%
↓+260% vs avg
5yr avg: -7.1%
30Y Low-121%·High11%
Debt/EBITDA
↓
1.15
↓-21% vs avg
5yr avg: 1.47
30Y Low1.2·High1.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BWAY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BrainsWay Ltd. trades at 45.6x earnings, 16% above its 5-year average of 39.4x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 106%. On a free-cash-flow basis, the stock trades at 19.6x P/FCF, roughly in line with the 5-year average of 18.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $322M | $202M | $164M | $107M | $41M | $120M | $85M | $100M | — | — | — |
| Enterprise Value | $261M | $141M | $100M | $97M | $-6196565 | $104M | $68M | $79M | — | — | — |
| P/E Ratio → | 45.61 | 26.42 | 52.44 | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.12 | 3.83 | 4.00 | 3.38 | 1.50 | 4.04 | 3.84 | 4.33 | — | — | — |
| P/B Ratio | 4.76 | 2.75 | 2.63 | 2.58 | 0.90 | 2.09 | 4.31 | 4.13 | — | — | — |
| P/FCF | 19.63 | 12.30 | 25.23 | — | — | — | — | — | — | — | — |
| P/OCF | 17.73 | 11.10 | 15.94 | 83.66 | — | 135.68 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BWAY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
BrainsWay Ltd.'s enterprise value stands at 44.2x EBITDA, 59% above its 5-year average of 27.8x. The Healthcare sector median is 14.0x, placing the stock at a 215% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.67 | 2.45 | 3.06 | -0.23 | 3.50 | 3.10 | 3.41 | — | — | — |
| EV / EBITDA | 44.16 | 23.79 | 31.75 | — | — | — | — | — | — | — | — |
| EV / EBIT | 59.87 | 32.25 | 27.99 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 8.57 | 15.43 | — | — | — | — | — | — | — | — |
BWAY Profitability
Margins and return-on-capital ratios measuring operating efficiency
BrainsWay Ltd. earns an operating margin of 8.3%. Operating margins have expanded from -15.6% to 8.3% over the past 3 years, signaling improving operational efficiency. ROE of 11.4% is modest. ROIC of 61.2% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.4% | 75.4% | 74.6% | 73.9% | 73.8% | 77.7% | 77.1% | 77.8% | 78.1% | 76.7% | 78.9% |
| Operating Margin | 8.3% | 8.3% | 3.4% | -15.6% | -46.7% | -16.9% | -21.9% | -36.7% | -31.2% | -59.3% | -18.0% |
| Net Profit Margin | 14.6% | 14.6% | 7.1% | -13.2% | -49.1% | -21.8% | -24.4% | -44.7% | -39.5% | -63.3% | -20.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.4% | 11.4% | 5.6% | -9.7% | -26.0% | -16.8% | -24.6% | -66.3% | -65.9% | -61.3% | -20.7% |
| ROA | 7.4% | 7.4% | 3.7% | -6.6% | -19.0% | -11.8% | -14.8% | -33.1% | -25.6% | -30.0% | -11.4% |
| ROIC | 61.2% | 61.2% | 6.9% | -24.9% | -48.2% | -16.8% | -114.9% | -336.6% | -436.8% | -346.5% | -86.4% |
| ROCE | 5.1% | 5.1% | 2.1% | -9.1% | -20.6% | -10.7% | -16.3% | -35.9% | -28.3% | -36.3% | -12.6% |
BWAY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
BrainsWay Ltd. carries a Debt/EBITDA ratio of 1.2x, which is manageable (63% below the sector average of 3.1x). The company holds a net cash position — cash of $68M exceeds total debt of $7M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 2.0x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | 0.41 | 0.21 | 0.08 |
| Debt / EBITDA | 1.15 | 1.15 | 1.78 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.83 | -1.02 | -0.24 | -1.04 | -0.28 | -0.83 | -0.88 | -0.88 | -0.93 | -0.81 |
| Net Debt / EBITDA | -10.35 | -10.35 | -20.15 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -3.73 | -9.80 | — | — | — | — | — | — | — | — |
| Interest Coverage | 1.96 | 1.96 | 1.03 | -16.64 | -186.51 | -35.45 | -45.56 | -16.75 | -12.95 | -49.34 | -33.92 |
Net cash position: cash ($68M) exceeds total debt ($7M)
BWAY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BrainsWay Ltd.'s current ratio of 3.83x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.51x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.68x to 3.83x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | 3.83 | 5.19 | 5.68 | 7.14 | 7.22 | 3.57 | 4.29 | 1.62 | 2.92 | 2.98 |
| Quick Ratio | 3.51 | 3.51 | 4.90 | 5.30 | 6.66 | 7.20 | 3.51 | 4.25 | 1.61 | 2.87 | 2.85 |
| Cash Ratio | 3.07 | 3.07 | 4.52 | 4.71 | 5.84 | 6.33 | 2.53 | 3.26 | 1.08 | 2.37 | 2.09 |
| Asset Turnover | — | 0.47 | 0.43 | 0.50 | 0.42 | 0.39 | 0.65 | 0.60 | 0.69 | 0.41 | 0.58 |
| Inventory Turnover | 1.81 | 1.81 | 2.36 | 2.24 | 1.86 | 32.99 | 11.44 | 16.76 | 39.44 | 9.58 | 4.15 |
| Days Sales Outstanding | — | 28.51 | 40.90 | 43.41 | 65.06 | 77.93 | 95.81 | 94.11 | 88.46 | 95.83 | 92.23 |
BWAY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BrainsWay Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 3.8% | 1.9% | — | — | — | — | — | — | — | — |
| FCF Yield | 5.1% | 8.1% | 4.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $21M | $35M | $33M | $33M | $31M | $22M | $21M | $17M | $15M | $15M |
Peer Comparison
Compare BWAY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BWAYYou | $322M | 45.6 | 44.2 | 19.6 | 75.4% | 8.3% | 11.4% | 61.2% | 1.2 |
 STIM | $151M | -3.7 | — | — | 48.5% | -21.1% | -134.4% | -26.6% | — |
 NVCR | $2B | -13.0 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 LIVN | $3B | -12.9 | 12.4 | 18.2 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 GKOS | $8B | -40.7 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 ELMD | $214M | 30.0 | 18.3 | 19.3 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 ABT | $152B | 11.4 | 15.9 | 23.9 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $100B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $83B | 28.9 | 25.1 | 22.7 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 INVA | $2B | 6.9 | 5.6 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See BWAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BWAY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BWAY vs STIM
Side-by-side business, growth, and profitability comparison vs Neuronetics, Inc..
Start ComparisonBWAY — Frequently Asked Questions
Quick answers to the most common questions about buying BWAY stock.
What is BrainsWay Ltd.'s P/E ratio?
BrainsWay Ltd.'s current P/E ratio is 45.6x. The historical average is 39.4x. This places it at the 50th percentile of its historical range.
What is BrainsWay Ltd.'s EV/EBITDA?
BrainsWay Ltd.'s current EV/EBITDA is 44.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 27.8x.
What is BrainsWay Ltd.'s ROE?
BrainsWay Ltd.'s return on equity (ROE) is 11.4%. The historical average is -42.3%.
Is BWAY stock overvalued?
Based on historical data, BrainsWay Ltd. is trading at a P/E of 45.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BrainsWay Ltd.'s profit margins?
BrainsWay Ltd. has 75.4% gross margin and 8.3% operating margin.
How much debt does BrainsWay Ltd. have?
BrainsWay Ltd.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.